ArticleMicrobiology spectrum2025
High-throughput clinical antimicrobial susceptibility testing and drug-resistant subpopulation detection in Gram-negative bacteria.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interaction of β-Caryophyllene with a Simplified Membrane Model and Its Growth-Inhibitory Effect AgainstPathogens (Basel, Switzerland) · 2026Article
- Molecular characteristics and analysis of drug resistance-virulence correlation of carbapenem-resistantMicrobiology spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimized Easy and Zooming MTT (EZMTT)-based antimicrobial susceptibility testing (AST) method for Gram-negative bacteria demonstrated 5- to 20-fold enhanced sensitivity and improved the detection limit to approximately 1.13% ± 0.30% growth. This advancement enables the detection of drug-resistant subpopulations that were previously undetectable by the gold standard broth microdilution (BMD) method, which has a growth limitation of approximately 10.15% ± 4.70%. Consistent results were achieved through AST of 205 clinical bacterial samples using both the EZMTT and BMD methods. At 450 nm, the overall positive and negative compliance rates were 98.94% and 99.58%, respectively, with a kappa value of 0.981 and a 95% CI of 0.974-0.988. For each of the 23 antibiotics tested, compliance rates exceeded 90.00%, with kappa values above 0.794 ~ 1.000 for 21 of them. Notably, the AST screening identified a clinical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.